News
Why Advanced Accelerator Applications SA Acquired a Higher Price Today
Advanced Accelerator Applications (NASDAQ: AAAP) is up 10.5% at 11:42 a.m. EDT after announcing that it was being acquired by Novartis (NYSE: NVS) for approximately $3.9 billion.Advanced....
Why TransEnterix Stock Is Rebounding Today
TransEnterix (NYSEMKT: TRX), a small-cap robotic-surgery company, is on the rebound today with its shares up by 21.41% on heavy volume, as of 11:05 a.m. EDT.Prior to today's double-digit move,....
3 High-Yield International Stocks
Because of the generally more favorable corporate tax rates abroad, international stocks can, on occasion, offer enormous yields that are sustainable in the long term. The international investing....
2 Top Pharma Stocks on Sale This Week
Like most investors, I love a good bargain. So when the top pharma stocks Celgene Corporation (NASDAQ: CELG) and GlaxoSmithKline plc (NYSE: GSK) both crashed last week, it definitely caught my....
The 3 Best Diabetes Stocks to Buy in 2018
Diabetes is a chronic condition that occurs when the body loses its ability to properly metabolize sugar. Without treatment, people with diabetes end up with too much sugar flowing through their....
How to Invest in Healthcare
Ten thousand Americans will turn 65 years old every day from now through 2029. As those Americans age, they will transform our country's healthcare system -- to the tune of a 5.8% annual increase....
ResMed's Sales and Profits Rise
ResMed (NYSE: RMD), a medical device marker focused on continuous positive airway pressure (CPAP) machines and accessories, reported its fiscal first-quarter results on Thursday, Oct. 26. The....
3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year
It's been a banner year for anyone who started 2017 holding shares of AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), XOMA Corporation (NASDAQ: XOMA), or Dynavax Technologies Corporation (NASDAQ:....
5 Things You Need to Know From Gilead Sciences' Q3 Update
You could probably fit the number of people surprised by Gilead Sciences' (NASDAQ: GILD) third-quarter results inside a phone booth -- if you could even find one. Hepatitis C virus (HCV) drug....
Ending Obamacare's Cost-Sharing Reductions Will Lead to This Ironic Result
With open enrollment for the Affordable Care Act (ACA) just days away, you're liable to notice that Obamacare (the more common name for the ACA) will look a lot different in the upcoming year.Most....
A Me-Too Push By Biopharma Is Crowding the Psoriasis Market
A wave of R&D is leading to next-generation psoriasis drugs that work better than ever. That's great news for patients desperate for new treatment options, but it's bad news for biopharma....
3 Bright Spots in Merck's Q3 Results
You only had to look at Merck's (NYSE: MRK) stock movement to know that the big drugmaker's third-quarter results weren't too great. Merck's share price dropped after the company reported a 2%....
3 High-Yield Dividend Aristocrat Stocks
If dividend stocks were like golf, there would be an elite group of stocks with green jackets like golfing greats who win the Masters tournament get to wear. This group of winners is called the....
Vertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the Pipeline
Vertex Pharmaceuticals (NASDAQ: VRTX) reported solid third-quarter earnings, with sales of its cystic fibrosis drugs up 34% year over year. Nevertheless, investors rightfully have one eye on the....
Celgene At $100: Buy, Sell, or Hold?
It's been a rotten couple of weeks to be a shareholder of Celgene (NASDAQ: CELG). The biotech giant's shares have been in near-freefall after they reached an all-time high of $147 on Oct. 2.....
Here's Why ResMed Inc. Stock Spiked Today
Sleep apnea specialist, ResMed, Inc. (NYSE: RMD) pleased investors with a positive fiscal first-quarter report after the bell yesterday. Another quarter of double-digit year-to-year growth on the....
Why Shares of Cerner Corp. Are Down Today
Shares of Cerner (NASDAQ: CERN), a provider of technology and solutions to the healthcare industry, slumped on Friday following the company's third-quarter report. Cerner missed analyst estimates....
There's a Lot to Like in AbbVie's Q3 Update
AbbVie (NYSE: ABBV) has set a pattern in recent quarters of meeting or barely exceeding consensus analysts' earnings estimates. It's not that the big biotech hasn't performed well; rather,....
Quintiles IMS Holdings Is Firing on All Cylinders
Quintiles IMS Holdings (NYSE: Q), a service and information provider for the healthcare and life sciences industries, reported its third-quarter results on Thursday, Oct. 26. The company's results....
What's Causing Align Technology's Shares to Soar 14% Today
After reporting third-quarter financial results that beat industry watchers expectations, shares in Align Technology (NASDAQ: ALGN) are surging 14.1% higher at 11:30 a.m. EDT.Years of double-digit....
Cerner Corporation Unimpressive in 3rd Quarter, but Expects Better Days Ahead
Cerner Corporation (NASDAQ: CERN) started off 2017 with a bang, posting strong revenue and earnings growth in the first quarter. Things slowed down a bit in the second quarter, with the healthcare....
3 Key Things to Watch in Pfizer's Q3 Results
There wasn't much to get excited about the last time Pfizer (NYSE: PFE) reported its quarterly results. While the big pharma company beat analysts' consensus earnings estimate, it also posted a 2%....
Stop Panicking About Celgene
Judging by the market reaction to Celgene's (NASDAQ: CELG) third-quarter results, you'd think one of the Four Horsemen of the Apocalypse just rode down Wall Street. Or maybe two of them....
Align Technology Inc.'s 2017 Is Lining Up Nicely With Another Record Quarter
Align Technology (NASDAQ: ALGN) posted record-high revenue when it announced its first-quarter results earlier this year. The medical-device company, best known for its Invisalign clear aligners,....
Gilead Sciences Inc. Still Singing the HCV Blues in the 3rd Quarter
Surprisingly strong hepatitis C virus (HCV) sales helped Gilead Sciences (NASDAQ: GILD) enjoy better-than-expected results when the big biotech provided its second-quarter update in July. But that....